Cannabinoid receptor localization in brain

M Herkenham, A B Lynn, M D Little, M R Johnson, L S Melvin, B R de Costa, K C Rice, M Herkenham, A B Lynn, M D Little, M R Johnson, L S Melvin, B R de Costa, K C Rice

Abstract

[3H]CP 55,940, a radiolabeled synthetic cannabinoid, which is 10-100 times more potent in vivo than delta 9-tetrahydrocannabinol, was used to characterize and localize a specific cannabinoid receptor in brain sections. The potencies of a series of natural and synthetic cannabinoids as competitors of [3H]CP 55,940 binding correlated closely with their relative potencies in several biological assays, suggesting that the receptor characterized in our in vitro assay is the same receptor that mediates behavioral and pharmacological effects of cannabinoids, including human subjective experience. Autoradiography of cannabinoid receptors in brain sections from several mammalian species, including human, reveals a unique and conserved distribution; binding is most dense in outflow nuclei of the basal ganglia--the substantia nigra pars reticulata and globus pallidus--and in the hippocampus and cerebellum. Generally high densities in forebrain and cerebellum implicate roles for cannabinoids in cognition and movement. Sparse densities in lower brainstem areas controlling cardiovascular and respiratory functions may explain why high doses of delta 9-tetrahydrocannabinol are not lethal.

References

    1. J Clin Pharmacol. 1981 Aug-Sep;21(8-9 Suppl):413S-416S
    1. J Biol Chem. 1951 Nov;193(1):265-75
    1. Ann Neurol. 1983 Jun;13(6):669-71
    1. Neuropeptides. 1983 Oct;3(6):493-9
    1. J Neurosci. 1984 Aug;4(8):2133-44
    1. J Pharmacol Exp Ther. 1985 Sep;234(3):784-91
    1. NIDA Res Monogr. 1985;62:30-50
    1. J Neurosci. 1986 Jan;6(1):199-207
    1. Alcohol Drug Res. 1985-1986;6(5):309-25
    1. Proc Natl Acad Sci U S A. 1986 Jun;83(11):4053-7
    1. Pharmacol Rev. 1986 Mar;38(1):1-20
    1. Pharmacol Rev. 1986 Jun;38(2):151-78
    1. Pharmacol Rev. 1986 Jun;38(2):75-149
    1. Mol Pharmacol. 1986 Oct;30(4):329-37
    1. Brain Res. 1986 Sep 24;383(1-2):121-8
    1. J Neurosci. 1986 Nov;6(11):3177-88
    1. J Pharmacol Exp Ther. 1986 Dec;239(3):941-5
    1. Psychopharmacology (Berl). 1987;91(1):20-4
    1. Mol Pharmacol. 1988 Mar;33(3):297-302
    1. J Pharmacol Exp Ther. 1988 Apr;245(1):178-86
    1. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
    1. Psychol Bull. 1967 Jun;67(6):416-22
    1. J Pharm Sci. 1974 Jul;63(7):1056-64
    1. J Med Chem. 1975 Jul;18(7):700-3
    1. J Med Chem. 1976 Sep;19(9):1165-7
    1. Life Sci. 1978 Apr 3-17;22(13-15):1131-7
    1. J Pharm Pharmacol. 1979 Apr;31(4):224-30
    1. J Med Chem. 1979 Jul;22(7):886-8
    1. J Pharmacol Exp Ther. 1980 Jul;214(1):124-30
    1. Neuroscience. 1988 Jun;25(3):771-95
    1. FASEB J. 1988 Nov;2(14):3022-6
    1. J Pharmacol Exp Ther. 1988 Nov;247(2):405-16
    1. Mol Pharmacol. 1988 Nov;34(5):605-13
    1. J Pharmacol Exp Ther. 1988 Dec;247(3):1046-51
    1. Psychopharmacology (Berl). 1988;95(4):507-11
    1. Psychopharmacology (Berl). 1988;96(1):142-4
    1. Trends Neurosci. 1988 Jun;11(6):244-8
    1. Brain Res. 1988 Jun 7;451(1-2):59-68
    1. Psychol Bull. 1983 May;93(3):441-56

Source: PubMed

3
Suscribir